Early findings after integration of donor‐derived cell‐free DNA into clinical care following pediatric heart transplantation

Abstract

dd-cfDNA assessment in place of selected, per-protocol EMB decreased surveillance EMB by 81% in our pediatric HT recipient cohort with no short-term adverse outcomes. Individual center approach to surveillance EMB will influence the utility of these findings.